SGLT2 inhibitors as add on therapy in type 2 diabetes: A real world study

被引：10

作者：

Tamez-Perez H.E. ^{[1
,2
]}

Delgadillo-Esteban E. ^{[1
]}

Soni-Duque D. ^{[2
]}

Hernández-Coria M.I. ^{[1
]}

Tamez-Peña A.L. ^{[1
]}

机构：

[1] Facultad de Medicina, Universidad Autónoma de Nuevo León, Subdirección de Investigación, Dr. Aguirre Pequeño, Mitras Centro, Monterrey, Nuevo León

[2] División de Medicina Interna Modelo Nova, Clínica Nova, Monterrey, Nuevo León

来源：

Journal of Diabetes & Metabolic Disorders | / 16卷 / 1期

关键词：

Canagliflozin; Dapagliflozin; Diabetes Mellitus; Type; 2; Effectiveness research; comparative; Hemoglobin A; Glycosylated;

D O I：

10.1186/s40200-017-0308-4

中图分类号：

学科分类号：

摘要：

Background: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. Methods: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes. Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals were established as <7%. Results: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of patients was 57.68 ± 11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19.44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, P < 0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was associated with better control (P < 0.05, 95% CI, [1.10, 3.92]). Conclusion: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as combined therapy. © 2017 The Author(s).

引用

共 15 条

[1]

Paneni F., Beckman J.A., Creager M.A., Cosentino F., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I, Eur Heart J, 34, (2013)

[2]

McGovern A., Et al., Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use, Diabetes Therapy, 8, 2, pp. 365-376, (2017)

[3]

Glycemic targets. Sec. 5. In Standards of Medical Care in Diabetes -2016, Diabetes Care, 39, pp. S39-S46, (2016)

[4]

Gallo L.A., Wright E.M., Vallon V., Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences, Diabetes Vasc Dis Res, 12, 2, pp. 78-89, (2015)

[5]

Gurgle H.E., White K., McAdam-Marx C., SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives, Vasc Health Risk Manag, 12, pp. 239-249, (2016)

[6]

Zinman B., Wanner C., Lachin J.M., Et al., Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, N Engl J Med, 373, 22, pp. 2117-2128, (2015)

[7]

R: A language and environment for statistical computing, (2016)

[8]

Rosenstock J., Hansen L., Zee P., Et al., Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A Randomized double- blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin, Diabetes Care, 38, 3, pp. 376-383, (2015)

[9]

Merovci A., Solis-Herrera C., Daniele G., Et al., Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production, J Clin Invest, 124, 2, pp. 509-514, (2014)

[10]

Nauck M.A., Prato S., Meier J.J., Et al., Dapagliflozin versus glipizide as add- on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active- controlled noninferiority trial, Diabetes Care, 34, 9, pp. 2015-2022, (2011)

← 1 2 →